Anti-Avelumab Antibodies
-
Bioanalytical Antibodies
-
Antibodies for Bioanalysis and Drug Monitoring
-
Our Anti-Biotherapeutic Antibodies
- Anti-Abatacept Antibodies
- Anti-Adalimumab Antibodies
- Anti-Aflibercept Antibodies
- Anti-Alemtuzumab Antibodies
- Anti-Atezolizumab Antibodies
- Anti-Avelumab Antibodies
- Anti-Belatacept Antibodies
- Anti-Bevacizumab Antibodies
- Anti-Brentuximab Antibodies
- Anti-Cemiplimab Antibodies
- Anti-Certolizumab Antibodies
- Anti-Cetuximab Antibodies
- Anti-Daratumumab Antibodies
- Anti-Denosumab Antibodies
- Anti-Dupilumab Antibodies
- Anti-Durvalumab Antibodies
- Anti-Eculizumab Antibodies
- Anti-Etanercept Antibodies
- Anti-Evolocumab Antibodies
- Anti-Golimumab Antibodies
- Anti-Infliximab Antibodies
- Anti-Ipilimumab Antibodies
- Anti-Natalizumab Antibodies
- Anti-Nivolumab Antibodies
- Anti-Obinutuzumab Antibodies
- Anti-Ocrelizumab Antibodies
- Anti-Omalizumab Antibodies
- Anti-Palivizumab Antibodies
- Anti-Panitumumab Antibodies
- Anti-Pembrolizumab Antibodies
- Anti-Pertuzumab Antibodies
- Anti-Ranibizumab Antibodies
- Anti-Rituximab Antibodies
- Anti-Sarilumab Antibodies
- Anti-Secukinumab Antibodies
- Anti-Tocilizumab Antibodies
- Anti-Trastuzumab Antibodies
- Anti-Ustekinumab Antibodies
- Anti-Vedolizumab Antibodies
-
Our Anti-Biotherapeutic Antibodies
-
Antibodies for Bioanalysis and Drug Monitoring
s
s
s
Antibodies for bioanalysis and drug monitoring of avelumab
Develop highly selective and sensitive PK and ADA assays for the antibody drug avelumab (Bavencio) using our range of ready-made anti-idiotypic antibodies.
- Highly specific to avelumab or the avelumab/PD-L1 complex
- Fully human surrogate positive control or calibrator
- Sequence defined, well characterized reagents with secure supply
- Recombinant production, stringent quality control for batch to batch consistency
- Non-animal-derived antibodies, reducing the use of animals in science
Table 1. Antibodies Specific to Avelumab and Avelumab/PD-L1 Complex
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
|---|---|---|---|---|---|---|
|
Avelumab Inhibitory Type 1 |
HCA396 |
AbD40519ia |
hIgG1 |
0.9 |
ADA assay |
|
|
HCA397 |
AbD40525ia |
hIgG1
|
11 |
ADA assay |
||
|
HCA398 |
AbD40526ia |
hIgG1 |
6 |
ADA assay |
||
|
TZA041 |
AbD40521ad |
Fab-F-Spy2-H1 |
1 |
PK bridging ELISA (capture) |
||
|
TZA040 |
AbD40519ad |
Fab-F-Spy2-H1 |
0.9 |
PK bridging ELISA (detection) |
||
|
TZA040P |
AbD40519pap |
Fab2-FH-X22-HRP2 |
0.9 |
PK bridging ELISA (detection) |
||
|
Avelumab / PD-L1 Complex Specific Type 3 |
TZA042 |
AbD42040ad |
Fab-F-Spy2-H1 |
4 |
PK ELISA antigen capture format (detection) |
|
|
TZA042P |
AbD42040pap |
Fab2-FH-X22-HRP2 |
4 |
PK ELISA antigen capture format (detection) |
* Affinity measured in the monovalent Fab format
1 Fab-F-Spy2-H = Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags
2 Fab2-FH-X22-HRP= Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags and Fab-SpyTag coupled to HRP conjugated BiCatcher
Anti-Avelumab Inhibitory Antibodies (Type 1)
The Type 1 anti-avelumab antibodies inhibit the binding of the drug avelumab to its target, programmed cell death ligand 1 (PD-L1). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format, they are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
Anti-Avelumab/PD-L1 Complex-Specific Antibodies (Type 3)
The Type 3 antibody specifically recognizes the drug-target complex, detecting avelumab only when it is bound to PD-L1. It is suitable as a detection antibody in a PK antigen capture assay.
ELISA Protocols to Get You Started
PK Bridging ELISA
Fig. 1. Avelumab PK bridging ELISA using antibodies TZA041 and TZA040P.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.
PK Antigen Capture ELISA
Fig. 2. Avelumab PK antigen capture ELISA using antibody TZA042P.
Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug target complex detection antibody, monovalent Fab format (purple), labeled with HRP.
ADA Bridging ELISA
Fig. 3. Avelumab ADA bridging ELISA using antibody HCA396, HCA397, and HCA398.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Related Product
Resources
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.